Citations (52)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Yahui Zhu, Jing Zhou, Lijing Zhu, Wenjing Hu, Baorui Liu & Li Xie. (2022) Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer. Human Vaccines & Immunotherapeutics 18:5.
Read now
Read now
Ning Xu, Benjamin Tse, Lu Yang, Tiffany C Y Tang, Michelle Haber, Kenneth Micklethwaite & Alla Dolnikov. (2021) Priming Leukemia with 5-Azacytidine Enhances CAR T Cell Therapy. ImmunoTargets and Therapy 10, pages 123-140.
Read now
Read now
Kenneth P. Seastedt, Nathanael Pruett & Chuong D. Hoang. (2021) Mouse models for mesothelioma drug discovery and development. Expert Opinion on Drug Discovery 16:6, pages 697-708.
Read now
Read now
Ben Wylie, Jonathan Chee, Catherine A Forbes, Mitchell Booth, Shane R Stone, Anthony Buzzai, Ana Abad, Bree Foley, Mark N Cruickshank & Jason Waithman. (2019) Acquired resistance during adoptive cell therapy by transcriptional silencing of immunogenic antigens. OncoImmunology 8:8.
Read now
Read now
Articles from other publishers (48)
Teresa Maria Rosaria Noviello, Anna Maria Di Giacomo, Francesca Pia Caruso, Alessia Covre, Roberta Mortarini, Giovanni Scala, Maria Claudia Costa, Sandra Coral, Wolf H. Fridman, Catherine Sautès-Fridman, Silvia Brich, Giancarlo Pruneri, Elena Simonetti, Maria Fortunata Lofiego, Rossella Tufano, Davide Bedognetti, Andrea Anichini, Michele Maio & Michele Ceccarelli. (2023) Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial. Nature Communications 14:1.
Crossref
Crossref
Haonan Jiang, Guzhanuer Awuti & Xiaoqing Guo. (2023) Construction of an Immunophenoscore-Related Signature for Evaluating Prognosis and Immunotherapy Sensitivity in Ovarian Cancer. ACS Omega 8:36, pages 33017-33031.
Crossref
Crossref
Kenneth K. W. To & William C. Cho. (2023) Drug Repurposing to Circumvent Immune Checkpoint Inhibitor Resistance in Cancer Immunotherapy. Pharmaceutics 15:8, pages 2166.
Crossref
Crossref
Fengyun Zhong, Yilin Lin, Long Zhao, Changjiang Yang, Yingjiang Ye & Zhanlong Shen. (2023) Reshaping the tumour immune microenvironment in solid tumours via tumour cell and immune cell DNA methylation: from mechanisms to therapeutics. British Journal of Cancer 129:1, pages 24-37.
Crossref
Crossref
Brandon L. McClellan, Santiago Haase, Felipe J. Nunez, Mahmoud S. Alghamri, Ali A. Dabaja, Pedro R. Lowenstein & Maria G. Castro. (2023) Impact of epigenetic reprogramming on antitumor immune responses in glioma. Journal of Clinical Investigation 133:2.
Crossref
Crossref
Michael Conroy, Áine O’Connor, Maeve Bailey-Whyte & Catríona M. Dowling. 2023. Epigenetic Cancer Therapy. Epigenetic Cancer Therapy
237
274
.
Andrea Anichini, Alessandra Molla, Gabriella Nicolini, Valentina Eleonora Perotti, Francesco Sgambelluri, Alessia Covre, Carolina Fazio, Maria Fortunata Lofiego, Anna Maria Di Giacomo, Sandra Coral, Antonella Manca, Maria Cristina Sini, Marina Pisano, Teresa Noviello, Francesca Caruso, Silvia Brich, Giancarlo Pruneri, Andrea Maurichi, Mario Santinami, Michele Ceccarelli, Giuseppe Palmieri, Michele Maio & Roberta Mortarini. (2022) Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy. Journal of Experimental & Clinical Cancer Research 41:1.
Crossref
Crossref
Zhengqing Song, Lili Lu, Zixu Gao, Qiwen Zhou, Zhiming Wang, Lei Sun & Yuhong Zhou. (2022) Immunotherapy for liposarcoma: emerging opportunities and challenges. Future Oncology 18:30, pages 3449-3461.
Crossref
Crossref
Kasturee Chakraborty, Archana Tripathi, Sukumar Mishra, Argha Mario Mallick & Rituparna Sinha Roy. (2022) Emerging concepts in designing next-generation multifunctional nanomedicine for cancer treatment. Bioscience Reports 42:7.
Crossref
Crossref
Yang Xu, Ping Li, Yang Liu, Dijia Xin, Wen Lei, Aibin Liang, Weidong Han & Wenbin Qian. (2022) Epi‐immunotherapy for cancers: rationales of epi‐drugs in combination with immunotherapy and advances in clinical trials. Cancer Communications 42:6, pages 493-516.
Crossref
Crossref
Abdullah KARAMAN & Elif KARLIK. (2022) İnsan Endojen Retrovirüslerin Kanserle Olan İlişkisinin İncelenmesiInvestigation of the Relationship of Human Endogenous Retroviruses with Cancer. International Journal of Life Sciences and Biotechnology 5:1, pages 110-130.
Crossref
Crossref
Sashana Dixon, Alice Tran, Matthew Schrier & Malav Trivedi. 2022. Engineering Technologies and Clinical Translation. Engineering Technologies and Clinical Translation
331
356
.
Maria Fortunata Lofiego, Sara Cannito, Carolina Fazio, Francesca Piazzini, Ornella Cutaia, Laura Solmonese, Francesco Marzani, Carla Chiarucci, Anna Maria Di Giacomo, Luana Calabrò, Sandra Coral, Michele Maio & Alessia Covre. (2021) Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy. Epigenomes 5:4, pages 27.
Crossref
Crossref
Julie Sanceau & Angélique Gougelet. (2021) Epigenetic mechanisms of liver tumor resistance to immunotherapy. World Journal of Hepatology 13:9, pages 979-1002.
Crossref
Crossref
Emilio Francesco Giunta, Gianluca Arrichiello, Marcello Curvietto, Annalisa Pappalardo, Davide Bosso, Mario Rosanova, Anna Diana, Pasqualina Giordano, Angelica Petrillo, Piera Federico, Teresa Fabozzi, Sara Parola, Vittorio Riccio, Brigitta Mucci, Vito Vanella, Lucia Festino, Bruno Daniele, Paolo Antonio Ascierto & Margaret Ottaviano. (2021) Epigenetic Regulation in Melanoma: Facts and Hopes. Cells 10:8, pages 2048.
Crossref
Crossref
Alejandra Fernandez, Connor O’Leary, Kenneth J O’Byrne, Joshua Burgess, Derek J Richard & Amila Suraweera. (2021) Epigenetic Mechanisms in DNA Double Strand Break Repair: A Clinical Review. Frontiers in Molecular Biosciences 8.
Crossref
Crossref
P.J. Vlachostergios. (2021) Polycomb repressive complex 2 mutations predict survival benefit in advanced cancer patients treated with immune checkpoint inhibitors. Immuno-Oncology and Technology 10, pages 100035.
Crossref
Crossref
Giuseppe Palmieri, Carla Maria Rozzo, Maria Colombino, Milena Casula, Maria Cristina Sini, Antonella Manca, Marina Pisano, Valentina Doneddu, Panagiotis Paliogiannis & Antonio Cossu. (2021) Are Molecular Alterations Linked to Genetic Instability Worth to Be Included as Biomarkers for Directing or Excluding Melanoma Patients to Immunotherapy?. Frontiers in Oncology 11.
Crossref
Crossref
Karthik Dhatchinamoorthy, Jeff D. Colbert & Kenneth L. Rock. (2021) Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation. Frontiers in Immunology 12.
Crossref
Crossref
Shaymaa Sadeq, Surar Al-Hashimi, Carmen M. Cusack & Andreas Werner. (2021) Endogenous Double-Stranded RNA. Non-Coding RNA 7:1, pages 15.
Crossref
Crossref
Yuan Wei, Xiao Xiao, Xiang-Ming Lao, Limin Zheng & Dong-Ming Kuang. (2020) Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors. Cellular and Molecular Life Sciences 78:3, pages 867-887.
Crossref
Crossref
A. M. Di Giacomo, Elisabetta Gambale & Michele Maio. 2021. New Therapies in Advanced Cutaneous Malignancies. New Therapies in Advanced Cutaneous Malignancies
281
310
.
Miaoqin Chen, Shiman Hu, Yiling Li, Ting Ting Jiang, Hongchuan Jin & Lifeng Feng. (2020) Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies. Signal Transduction and Targeted Therapy 5:1.
Crossref
Crossref
Simon J. Hogg, Paul A. Beavis, Mark A. Dawson & Ricky W. Johnstone. (2020) Targeting the epigenetic regulation of antitumour immunity. Nature Reviews Drug Discovery 19:11, pages 776-800.
Crossref
Crossref
Lorea Villanueva, Damiana Álvarez-Errico & Manel Esteller. (2020) The Contribution of Epigenetics to Cancer Immunotherapy. Trends in Immunology 41:8, pages 676-691.
Crossref
Crossref
Qingyang Xiao, André Nobre, Pilar Piñeiro, Miguel-Ángel Berciano-Guerrero, Emilio Alba, Manuel Cobo, Volker Lauschke & Isabel Barragán. (2020) Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response. Journal of Clinical Medicine 9:1, pages 286.
Crossref
Crossref
Anna Maria Di Giacomo, Alessia Covre, Francesca Finotello, Dietmar Rieder, Riccardo Danielli, Luca Sigalotti, Diana Giannarelli, Florent Petitprez, Laetitia Lacroix, Monica Valente, Ornella Cutaia, Carolina Fazio, Giovanni Amato, Andrea Lazzeri, Santa Monterisi, Clelia Miracco, Sandra Coral, Andrea Anichini, Christoph Bock, Amelie Nemc, Aram Oganesian, James Lowder, Mohammad Azab, Wolf H. Fridman, Catherine Sautès-Fridman, Zlatko Trajanoski & Michele Maio. (2019) Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial. Clinical Cancer Research 25:24, pages 7351-7362.
Crossref
Crossref
Abdullah Al Emran, Aniruddha Chatterjee, Euan J. Rodger, Jessamy C. Tiffen, Stuart J. Gallagher, Michael R. Eccles & Peter Hersey. (2019) Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy. Trends in Immunology 40:4, pages 328-344.
Crossref
Crossref
Ali Akbar Samadani, Seyedeh Elham Noroollahi, Fariborz Mansour-Ghanaei, Ali Rashidy-Pour, Farahnaz Joukar & Ahmad Reza Bandegi. (2019) Fluctuations of epigenetic regulations in human gastric Adenocarcinoma: How does it affect?. Biomedicine & Pharmacotherapy 109, pages 144-156.
Crossref
Crossref
Carolina Fazio, Alessia Covre, Ornella Cutaia, Maria Fortunata Lofiego, Patrizia Tunici, Carla Chiarucci, Sara Cannito, Gianluca Giacobini, James N. Lowder, Roberta Ferraldeschi, Pietro Taverna, Anna Maria Di Giacomo, Sandra Coral & Michele Maio. (2018) Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy. Frontiers in Pharmacology 9.
Crossref
Crossref
Lei Cai, Theodoros Michelakos, Teppei Yamada, Song Fan, Xinhui Wang, Joseph H. Schwab, Cristina R. Ferrone & Soldano Ferrone. (2018) Defective HLA class I antigen processing machinery in cancer. Cancer Immunology, Immunotherapy 67:6, pages 999-1009.
Crossref
Crossref
Robert J. Soiffer, Matthew S. Davids & Yi-Bin Chen. (2018) Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation. Blood 131:10, pages 1073-1080.
Crossref
Crossref
Elizabeth A. Griffiths, Pragya Srivastava, Junko Matsuzaki, Zachary Brumberger, Eunice S. Wang, Justin Kocent, Austin Miller, Gregory W. Roloff, Hong Yuen Wong, Benjamin E. Paluch, Linda G. Lutgen-Dunckley, Brandon L. Martens, Kunle Odunsi, Adam R. Karpf, Christopher S. Hourigan & Michael J. Nemeth. (2018) NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome. Clinical Cancer Research 24:5, pages 1019-1029.
Crossref
Crossref
Hongjuan Zhao, Shoucheng Ning, Rosalie Nolley, Jan Scicinski, Bryan Oronsky, Susan J. Knox & Donna M. Peehl. (2017) The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry. Clinical Epigenetics 9:1.
Crossref
Crossref
Tan Boon Toh, Jhin Jieh Lim & Edward Kai-Hua Chow. (2017) Epigenetics in cancer stem cells. Molecular Cancer 16:1.
Crossref
Crossref
E. Giovannetti, P.A. Zucali, Y.G. Assaraf, N. Funel, M. Gemelli, M. Stark, E. Thunnissen, Z. Hou, I.B. Muller, E.A. Struys, M. Perrino, G. Jansen, L.H. Matherly & G.J. Peters. (2017) Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools. Annals of Oncology 28:11, pages 2725-2732.
Crossref
Crossref
Xiaoyan Liu, Qing Zhou, Yan Xu, Minjiang Chen, Jing Zhao & Mengzhao Wang. (2017) Harness the synergy between targeted therapy and immunotherapy: what have we learned and where are we headed?. Oncotarget 8:49, pages 86969-86984.
Crossref
Crossref
Nisha Padmanabhan, Toshikazu Ushijima & Patrick Tan. (2017) How to stomach an epigenetic insult: the gastric cancer epigenome. Nature Reviews Gastroenterology & Hepatology 14:8, pages 467-478.
Crossref
Crossref
Stuart J Gallagher, Elena Shklovskaya & Peter Hersey. (2017) Epigenetic modulation in cancer immunotherapy. Current Opinion in Pharmacology 35, pages 48-56.
Crossref
Crossref
Hai Chen, Xiaodong Qi, Xue Bai, Ping Qiu & Bin Chen. (2017)
Role of
CD152
genetic polymorphisms in the susceptibility to breast cancer
. Oncotarget 8:16, pages 26679-26686.
Crossref
Crossref
Cinzia Solinas, Andrea Gombos, Sofiya Latifyan, Martine Piccart-Gebhart, Marleen Kok & Laurence Buisseret. (2017) Targeting immune checkpoints in breast cancer: an update of early results. ESMO Open 2:5, pages e000255.
Crossref
Crossref
Siwen Hu-Lieskovan & Antoni Ribas. (2017) New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone. The Cancer Journal 23:1, pages 10-22.
Crossref
Crossref
Pornpimol Charoentong, Francesca Finotello, Mihaela Angelova, Clemens Mayer, Mirjana Efremova, Dietmar Rieder, Hubert Hackl & Zlatko Trajanoski. (2017) Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. Cell Reports 18:1, pages 248-262.
Crossref
Crossref
Maarten Swart, Inge Verbrugge & Joost B. Beltman. (2016) Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy. Frontiers in Oncology 6.
Crossref
Crossref
Maximilian Stahl, Nathan Kohrman, Steven D. Gore, Tae Kon Kim, Amer M. Zeidan & Thomas Prebet. (2016) Epigenetics in Cancer: A Hematological Perspective. PLOS Genetics 12:10, pages e1006193.
Crossref
Crossref
Anna E Vilgelm, Douglas B Johnson & Ann Richmond. (2016) Combinatorial approach to cancer immunotherapy: strength in numbers. Journal of Leukocyte Biology 100:2, pages 275-290.
Crossref
Crossref
A.R. Maiuri & H.M. O’Hagan. 2016. Molecular and Cellular Changes in the Cancer Cell. Molecular and Cellular Changes in the Cancer Cell
69
117
.
Michele Maio, Alessia Covre, Elisabetta Fratta, Anna Maria Di Giacomo, Pietro Taverna, Pier Giorgio Natali, Sandra Coral & Luca Sigalotti. (2015) Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy. Clinical Cancer Research 21:18, pages 4040-4047.
Crossref
Crossref